Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells

Cell Cycle

Volumn 9, Issue 7, 2010, Pages 1399-1410

  Cusimano, Antonella ^a   Azzolina, Antonina ^a   Iovanna, Juan L ^b   Bachvarov, Dimcho ^c,d   McCubrey, James A ^e   D'Alessandro, Natale ^f   Montalto, Giuseppe ^f   Cervello, Melchiorre ^a  

^a CNR   (Italy)

^b INSERM   (France)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e EAST CAROLINA UNIVERSITY   (United States)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Celecoxib; COX 2; ER stress response; HCC; MG132; Proteasome; TRB3; UPR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 7; CELECOXIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SMALL INTERFERING RNA; X BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN CLEAVAGE; RNA SPLICING; TRB3 GENE; WESTERN BLOTTING;

EID: 77953552589     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.7.11254     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LM. Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963:13-20.
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48:1312-27.
4. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36:885-94.
5. Foderà D, D'Alessandro N, Cusimano A, Poma P, Notarbartolo M, Lampiasi N, et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 2004; 1028:440-9.
6. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98:736-47. (Pubitemid 43983297)
7. Schmidt CM, Wang Y, Wiesenauer C. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg 2003; 7:1024-33. (Pubitemid 37524070)
8. Cusimano A, Foderà D, D'Alessandro N, Lampiasi N, Azzolina A, Montalto G, et al. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Therapy 2007; 6:1461-8. (Pubitemid 351590359)
9. Tsutsumi S, Namba T, Tanaka KI, Arai Y, Ishihara T, Aburaya M, et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 2006; 25:1018-29. (Pubitemid 43277010)
10. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 2008; 68:843-51.
11. Cho HY, Thomas S, Golden EB, Gaffney KJ, Hofman FM, Chen TC, et al. Enhanced killing of chemoresistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett 2009; 282:87-97.
12. 2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 2005; 280:31059-67.
13. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104:1794-807. (Pubitemid 41513161)
14. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11:51-61. (Pubitemid 43152686)
15. Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009; 8:1940-51.
16. Cervello M, Giannitrapani L, La Rosa M, Notarbartolo M, Labbozzetta M, Poma P, et al. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of β-catenin and inhibition of β-catenin-mediated transactivation. Int J Mol Med 2004; 13:741-8.
17. Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, et al. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 2006; 11:607-25.
18. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100:9946-51.
19. Ustundag Y, Bronk SF, Gores GJ. Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol 2007; 13:851-7.
20. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65:11510-9.
21. Davenport EL, Morgan GJ, Davies FE. Untangling the unfolded protein response. Cell Cycle 2008; 7:865-9.
22. Lisbona F, Hetz C. Turning off the unfolded protein response: an interplay between the apoptosis machinery and ER stress signaling. Cell Cycle 2009; 8:1643-4.
23. Li J, Lee AS. Stress induction of GRP78/BIP and its role in cancer. Curr Mol Med 2006; 6:5-54.
24. Lee AH, Iwaskoshi NN, Glimcher H. XBP1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003; 23:7448-59.
25. Zinszner H, Kuroda M, Wang XZ, Batchavarova N, Lightfoot RT, Remotti H, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998; 12:982-95.
26. Matsukawa J, Matsuzawa A, Takeda k, Ichijo H. The ASK1-MAP kinase cascades in mammalian stress responses. J Biochem 2004; 136:261-5.
27. Haidara K, Marion M, Gascon-Barrè M, Denizeau F, Averil-Bates DA. Implication of caspases and subcellular compartments in tert-butylhydroperoxide induced apoptosis. Toxicol Appl Pharmacol 2008; 229:65-76.
28. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3 a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J 2005; 24:1243-55.
29. Schönthal AH. Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett 2009; 275:163-9.
30. Chen F, Castranova V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 2009; 8:1145-7.
31. Honmo S, Ozaki A, Yamamoto M, Hashimoto N, Miyakoshi M, Tanaka H, et al. Low p38 MAPK and JNK activation in cultured hepatocytes of DRH rats; a strain highly resistant to hepatocarcinogenesis. Mol Carcinog 2007; 46:758-65.
32. Ishizawa J, Yoshida S, Oya M, Mizuno R, Shinojima T, Marumo K, et al. Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int J Oncol 2004; 25:697-702.
33. Wang HQ, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY, et al. Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression. Br J Pharmacol 2009; 158:1405-12.
34. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205-19.
35. de Groot DJ, de Vries EG, Groen HJ, de Jong S. Nonsteroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007; 61:52-69.
36. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006; 13:363-73.
37. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcino-genesis. J Hepatol 2003; 38:605-14.
38. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11:381-9.
39. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by downregulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001; 21:1249-59.
40. Carracedo A, Lorente M, Egia A, Blázquez C, García S, Giroux V, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006; 9:301-12.
41. Yy Ord D, Meerits K, Ord T. TRB3 protects cells against the growth inhibitory and cytotoxic effect of ATF4. Exp Cell Res 2007; 313:3556-67.
42. Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D'Alessandro N, Lampiasi N, et al. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann NY Acad Sci 2004; 1028:432-49.
43. Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, et al. Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: A possible role in the growth-regulatory effects of the cytokine? Eur J Cancer 2001; 37:512-9.